Patients who were FLT3-ITD-mutated but NPM1 wild type AML had the shortest duration of remission among the subgroups evaluated (median 10.1 months versus 18.4 months for FLT3 wild type AML). This evidence concerns the gene NPM1 and acute myeloid leukemia.